NYSE:DVA
DAVITA INC.
A major US-based dialysis services provider with a vast clinic network serving chronic kidney disease patients primarily through Medicare contracts.
Key Metrics
Investment Thesis
Bull Case
The stock offers compelling value through consistent revenue growth driven by an aging population increasing dialysis demand while maintaining strong cash generation capabilities. Shareholder-friendly capital allocation strategies including aggressive buybacks support per-share value creation and provide downside protection during market volatility. Established market leadership positions across multiple geographic regions create a defensive characteristic attractive in uncertain economic environments.
Bear Case
Declining profit margins despite revenue expansion signal underlying profitability challenges that could persist if regulatory headwinds continue to intensify. Heavy reliance on Medicare reimbursement rates exposes the business to unpredictable policy changes that may significantly impact future earnings trajectories. High levels of goodwill assets combined with accumulated other comprehensive losses indicate potential balance sheet weakness requiring careful monitoring.
About DAVITA INC.
DAVITA INC. is a leading provider of dialysis services operating across the United States, serving patients with chronic kidney disease through its extensive network of clinics. The company generates revenue primarily from Medicare reimbursements and private insurance contracts, offering comprehensive renal care solutions including home dialysis programs. Its operational model focuses on delivering high-quality patient outcomes while managing complex regulatory environments within the healthcare sector.
Analysis
Management Discussion
Recent financial performance shows a decline in net profit to $1.08B from the previous year's $1.25B despite revenue growth to $13.64B, indicating margin compression pressures. The company deployed substantial cash for share repurchases of $1.31B while investing $575.9M in capital expenditures, reflecting a balance between shareholder returns and infrastructure modernization. Cash flow from operations remains robust at $1.89B providing liquidity to fund acquisitions totaling $117.5M and manage debt obligations.
Industry Overview
The dialysis services industry is experiencing steady growth driven by increasing prevalence of chronic kidney disease and an aging demographic across developed markets. Competition has intensified as traditional provider models face challenges from alternative care settings and technology-enabled home treatment solutions. Regulatory frameworks continue to evolve with greater emphasis on value-based care metrics rather than pure volume-based reimbursement structures.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $11.61B | $12.14B | $12.82B | $13.64B |
| Cost of Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | $11.61B | $12.14B | $12.82B | $13.64B |
| Operating Expenses | $10.27B | $10.54B | $10.73B | $11.60B |
| Operating Income | $1.34B | $1.60B | $2.09B | $2.04B |
| G&A | $1.36B | $1.47B | $1.54B | $1.67B |
| Stock-Based Comp | $95.4M | $112.4M | $102.8M | $140.0M |
| D&A | $721.1M | $736.5M | $716.4M | $708.3M |
| Amortization | $11.5M | $9.0M | $7.5M | $7.1M |
| Other OpEx | $8.92B | $9.06B | $9.19B | $9.93B |
| Non-Operating Income | $-372.8M | $-425.7M | $-560.1M | $-696.8M |
| Pre-Tax Income | $966.3M | $1.18B | $1.53B | $1.35B |
| Income Tax | $198.1M | $220.1M | $279.7M | $293.1M |
| Continuing Ops | $768.2M | $957.0M | $1.25B | $1.05B |
| Discontinued Ops | $13.5M | $0 | $0 | $25.0M |
| Net Income | $781.6M | $957.0M | $1.25B | $1.08B |
| Minority Interest | $221.2M | $265.4M | $314.4M | $331.9M |
| Net to Common | $560.4M | $691.5M | $936.3M | $746.8M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $3.16B | $3.14B | $3.75B | $4.06B |
| Cash & Equivalents | $244.1M | $380.1M | $794.9M | $676.4M |
| Marketable Securities | $77.7M | $11.6M | $51.1M | $24.3M |
| Accounts Receivable | $2.13B | $1.99B | $2.15B | $2.41B |
| Inventory | $109.1M | $143.1M | $134.6M | $160.6M |
| Prepaid Expenses | $78.8M | $102.6M | $122.9M | $156.3M |
| Other Current Assets | $513.5M | $513.6M | $495.6M | $625.7M |
| Long-Term Assets | $13.77B | $13.76B | $13.54B | $13.42B |
| PP&E (Net) | $3.26B | $3.07B | $2.94B | $2.81B |
| Intangibles | $182.7M | $203.2M | $197.4M | $222.1M |
| Goodwill | $7.08B | $7.11B | $7.38B | $7.55B |
| Operating Leases | $2.67B | $2.50B | $2.39B | $2.40B |
| LT Securities | $44.3M | $47.9M | $33.7M | $41.0M |
| Other LT Assets | $546.7M | $817.1M | $598.4M | $403.8M |
| Total Assets | $16.93B | $16.89B | $17.29B | $17.48B |
| Current Liabilities | $2.62B | $2.64B | $2.97B | $3.14B |
| Accounts Payable | $479.8M | $514.5M | $547.2M | $696.1M |
| Current Leases | $395.4M | $394.4M | $410.4M | $425.5M |
| Taxes Payable | $18.0M | $28.5M | $10.3M | $24.4M |
| Other Current Liab | $1.73B | $1.70B | $2.01B | $2.00B |
| Long-Term Liabilities | $12.08B | $11.51B | $12.22B | $13.18B |
| LT Operating Leases | $2.50B | $2.33B | $2.21B | $2.18B |
| Other LT Liab | $9.58B | $9.18B | $10.01B | $11.00B |
| Total Liabilities | $14.70B | $14.15B | $15.19B | $16.32B |
| Shareholders' Equity | $2.22B | $2.74B | $2.09B | $1.16B |
| Retained Earnings | $174.5M | $598.3M | $1.53B | $-328.4M |
| AOCI | $-69.2M | $-52.1M | $-310.8M | $-122.8M |
| Treasury Stock | — | — | $1.39B | $199.9M |
| Total L&E | $16.93B | $16.89B | $17.29B | $17.48B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $781.6M | $957.0M | $1.25B | $1.08B |
| Non-Cash Adjustments | $411.0M | $1.13B | $680.2M | $405.1M |
| Working Capital Changes | $372.0M | $-30.9M | $91.1M | $402.7M |
| Cash from Operations | $1.56B | $2.06B | $2.02B | $1.89B |
| Capital Expenditures | $603.4M | $568.0M | $555.4M | $575.9M |
| Cash from Investing | $-630.3M | $-771.8M | $-771.4M | $-654.9M |
| Debt Issuances | $2.39B | $2.47B | $6.62B | $5.61B |
| Share Buybacks | $802.2M | $272.2M | $1.39B | $1.31B |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Cash from Financing | $-1.12B | $-1.17B | $-816.9M | $-1.37B |
| FX Effect | $-29.1M | $8.9M | $-18.5M | $21.2M |
| Net Change in Cash | $-216.0M | $125.6M | $415.2M | $-122.1M |
| Beginning Cash | $555.0M | $339.0M | $464.6M | $879.8M |
| Ending Cash | $339.0M | $464.6M | $879.8M | $757.7M |
Frequently Asked Questions
How does DAVITA INC. make money?
The company's revenue is driven by its core dialysis services segment which serves as the primary income source, supplemented by home dialysis programs that offer alternative treatment settings. Additional streams include ancillary services such as renal nutrition and medical device sales integrated into patient care plans. The business also encompasses administrative operations supporting clinic efficiency and technology investments in telehealth monitoring.
What are the main risks for DVA?
Significant regulatory risk exists as changes to Medicare reimbursement rates or payment models could materially impact profitability margins. High dependency on government payments creates exposure to policy shifts that may reduce revenue per patient without commensurate cost reductions. Operational challenges include potential supply chain disruptions for medical devices and reagents essential for dialysis treatment delivery. Increasing competition from smaller regional providers and alternative care models threatens market share growth.
What is DVA's competitive advantage?
DAVITA benefits from significant scale advantages allowing it to negotiate favorable contracts with payers while maintaining lower per-patient operating costs through network density. Its extensive home dialysis program differentiation provides patients with greater treatment flexibility, fostering high patient retention rates and brand loyalty. Strong relationships with Medicare and commercial insurers provide stable revenue visibility despite ongoing regulatory scrutiny in the healthcare sector.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.